The introduction of molecular diagnostic tests provides an important step to address
the burden of sexually transmitted infections (STIs), especially Chlamydia trachomatis,
Neisseria gonorrhoeae, and Trichomonas vaginalis. Recently developed Xpert
CT/NG (for C. trachomatis/N. gonorrhoeae) and TV (for T. vaginalis) assays provide
opportunities to detect these STIs in resource-limited settings. When performed by
staff at primary health care (PHC) facilities, patients can be provided results and
treatment within 2 h.